You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 16, 2025

Acrotech Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Acrotech
International Patents:179
US Patents:12
Tradenames:6
Ingredients:6
NDAs:6

Drugs and US Patents for Acrotech

ApplicantTradenameGeneric NameDosageNDAApproval DateTETypeRLDRSPatent No.Patent ExpirationProductSubstanceDelist Req.Exclusivity Expiration
Acrotech Biopharma BELEODAQ belinostat POWDER;INTRAVENOUS 206256-001 Jul 3, 2014 RX Yes Yes 6,888,027 ⤷  Try for Free Y Y ⤷  Try for Free
Acrotech Biopharma EVOMELA melphalan hydrochloride POWDER;INTRAVENOUS 207155-001 Mar 10, 2016 RX Yes Yes 10,864,183 ⤷  Try for Free Y ⤷  Try for Free
Acrotech Biopharma FOLOTYN pralatrexate SOLUTION;INTRAVENOUS 022468-002 Sep 24, 2009 RX Yes Yes 8,299,078 ⤷  Try for Free ⤷  Try for Free
Acrotech Biopharma FUSILEV levoleucovorin calcium SOLUTION;INTRAVENOUS 020140-003 Apr 29, 2011 DISCN Yes No ⤷  Try for Free ⤷  Try for Free
Acrotech Biopharma KHAPZORY levoleucovorin POWDER;INTRAVENOUS 211226-001 Oct 19, 2018 RX Yes Yes 11,541,012 ⤷  Try for Free Y ⤷  Try for Free
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>TE>Type>RLD>RS>Patent No.>Patent Expiration>Product>Substance>Delist Req.>Exclusivity Expiration
Showing 1 to 5 of 5 entries

Expired US Patents for Acrotech

ApplicantTradenameGeneric NameDosageNDAApproval DatePatent No.Patent Expiration
Acrotech Biopharma FOLOTYN pralatrexate SOLUTION;INTRAVENOUS 022468-001 Sep 24, 2009 6,028,071 ⤷  Try for Free
Acrotech Biopharma FOLOTYN pralatrexate SOLUTION;INTRAVENOUS 022468-002 Sep 24, 2009 6,028,071 ⤷  Try for Free
Acrotech MARQIBO KIT vincristine sulfate INJECTABLE, LIPOSOMAL;INTRAVENOUS 202497-001 Aug 9, 2012 5,543,152 ⤷  Try for Free
Acrotech MARQIBO KIT vincristine sulfate INJECTABLE, LIPOSOMAL;INTRAVENOUS 202497-001 Aug 9, 2012 7,887,836 ⤷  Try for Free
Acrotech MARQIBO KIT vincristine sulfate INJECTABLE, LIPOSOMAL;INTRAVENOUS 202497-001 Aug 9, 2012 6,723,338 ⤷  Try for Free
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>Patent No.>Patent Expiration
Showing 1 to 5 of 5 entries
Paragraph IV (Patent) Challenges for ACROTECH drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Injection 20 mg/mL and 40 mg/2 mL ➤ Subscribe 2013-09-24
➤ Subscribe Injection 50 mg/vial ➤ Subscribe 2017-09-08
➤ Subscribe Injection 50 mg/vial ➤ Subscribe 2013-12-19
➤ Subscribe Injection 500 mg/vial ➤ Subscribe 2018-07-03
➤ Subscribe Injection 10 mg/mL, 17.5 mL vial and 25 mL vial ➤ Subscribe 2011-10-26

International Patents for Acrotech Drugs

CountryPatent NumberEstimated Expiration
Japan 2008540499 ⤷  Try for Free
Mexico 353603 ⤷  Try for Free
Singapore 11201503089W ⤷  Try for Free
World Intellectual Property Organization (WIPO) 2010138920 ⤷  Try for Free
World Intellectual Property Organization (WIPO) 2014066274 ⤷  Try for Free
>Country>Patent Number>Estimated Expiration
Showing 1 to 5 of 5 entries

Supplementary Protection Certificates for Acrotech Drugs

Patent NumberSupplementary Protection CertificateSPC CountrySPC ExpirationSPC Description
2701720 122023000007 Germany ⤷  Try for Free PRODUCT NAME: MELPHALANFLUFENAMID HYDROCHLORID; REGISTRATION NO/DATE: EU/1/22/1669 20220817
2701720 23C1000 France ⤷  Try for Free PRODUCT NAME: MELPHALAN FLUFENAMIDE ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, TELS QUE LE CHLORHYDRATE; REGISTRATION NO/DATE: EU/1/22/1669 20220818
2701720 3/2023 Austria ⤷  Try for Free PRODUCT NAME: MELPHALANFLUFENAMID-HYDROCHLORID; REGISTRATION NO/DATE: EU/1/22/1669 (MITTEILUNG) 20220818
2701720 CA 2022 00054 Denmark ⤷  Try for Free PRODUCT NAME: MELPHALAN FLUFENAMIDE HYDROCHLORIDE; REG. NO/DATE: EU/1/22/1669 20220818
2701720 CR 2022 00054 Denmark ⤷  Try for Free PRODUCT NAME: MELPHALAN FLUFENAMIDE HYDROCHLORIDE; REG. NO/DATE: EU/1/22/1669 20220818
>Patent Number>Supplementary Protection Certificate>SPC Country>SPC Expiration>SPC Description
Showing 1 to 5 of 5 entries
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Acrotech Biopharma: A Rising Star in the Pharmaceutical Competitive Landscape

In the ever-evolving world of pharmaceuticals, Acrotech Biopharma has emerged as a noteworthy player, carving out a unique position in the competitive landscape. Founded in 2018, this relatively young company has quickly made its mark, particularly in the oncology and hematology sectors. Let's dive into Acrotech's market position, strengths, and strategic insights that are shaping its trajectory in the pharmaceutical industry.

The Birth of Acrotech Biopharma

Acrotech Biopharma Inc., a subsidiary of Aurobindo Pharma USA, was established with a clear mission: to develop and commercialize innovative proprietary medications[1]. From its inception, the company set its sights on addressing unmet medical needs and delivering value to patients and healthcare stakeholders alike.

A Strategic Acquisition

Acrotech's journey took a significant turn in 2019 when it acquired seven FDA-approved hematology/oncology products from Spectrum Pharmaceuticals for $300 million[3]. This bold move instantly positioned Acrotech as a leader in specific therapeutic areas, particularly in peripheral T-cell lymphoma (PTCL)[9].

"We are excited to jump-start our mission of helping cancer patients across the globe by delivering clinically differentiated medications and leveraging strategic partnerships," said Dr. Ashish Anvekar, President of Acrotech[6].

Acrotech's Market Position

In a relatively short time, Acrotech has established itself as a significant player in the oncology and hematology markets. The company's focus on "diamonds-in-the-rough" - drugs with improved efficacy and/or safety over current treatments - has set it apart from competitors[9].

Product Portfolio

Acrotech currently markets five injectable oncology brands in the USA, with a strong presence in PTCL treatment[2]. Its product lineup includes well-recognized names such as Folotyn, Beleodaq, and Evomela, among others[3].

Global Reach

While Acrotech's primary market is the USA, the company has expanded its reach globally through strategic partnerships. These collaborations cover major markets including the EU, Canada, Japan, China, and Latin America[2].

Acrotech's Competitive Advantages

Several factors contribute to Acrotech's competitive edge in the pharmaceutical landscape:

1. Focused Strategy

Acrotech's strategy of targeting niche areas within oncology and hematology allows it to concentrate its resources effectively. This focused approach enables the company to compete with larger pharmaceutical giants in specific therapeutic areas.

2. Robust Commercial Infrastructure

The acquisition from Spectrum Pharmaceuticals not only brought valuable products but also an experienced commercial team. This infrastructure provides Acrotech with the capability to effectively market and distribute its products[6].

3. Patient-Centric Approach

Acrotech's commitment to patient care is evident in initiatives like the STAR program, which provides patient assistance for those who meet certain criteria[7]. This patient-focused approach enhances the company's reputation and builds brand loyalty.

Competitive Landscape Analysis

To understand Acrotech's position, it's crucial to examine the broader pharmaceutical competitive landscape:

Key Players

The pharmaceutical industry is dominated by giants like Pfizer, Johnson & Johnson, Novartis, and Merck & Co[4]. These companies have vast resources for R&D and global marketing capabilities.

Market Trends

Several trends are shaping the pharmaceutical industry:

  1. Personalized medicine
  2. Digital health integration
  3. Increasing focus on rare diseases
  4. Biosimilars and generics
  5. Emphasis on value-based care

Acrotech's Position

In this landscape, Acrotech has positioned itself as a specialist in oncology and hematology, with a particular focus on rare and uncommon diseases. This niche strategy allows Acrotech to compete effectively in specific areas without directly challenging the industry giants across all therapeutic categories.

Strategic Insights

Acrotech's strategy offers several insights for success in the pharmaceutical industry:

1. Niche Focus

By concentrating on specific therapeutic areas, Acrotech has been able to build expertise and a strong market position rapidly. This strategy can be particularly effective for smaller companies competing against industry giants.

2. Strategic Acquisitions

Acrotech's acquisition of Spectrum's portfolio demonstrates how strategic purchases can quickly establish a company's market presence and provide a foundation for growth.

3. Global Partnerships

Acrotech's approach to global expansion through partnerships allows it to extend its reach without the full cost and risk of establishing operations in each market.

4. Patient-Centric Programs

Initiatives like the STAR program show how pharmaceutical companies can build goodwill and address access issues, potentially leading to increased adoption and loyalty.

Challenges and Opportunities

While Acrotech has made significant strides, it faces several challenges and opportunities:

Challenges

  1. Competition from larger pharmaceutical companies
  2. Regulatory hurdles in drug development and approval
  3. Pricing pressures in the healthcare industry
  4. Need for continuous innovation to maintain market position

Opportunities

  1. Expansion into new therapeutic areas within oncology and hematology
  2. Development of biosimilars and generics
  3. Leveraging digital health technologies for patient care and drug development
  4. Exploring emerging markets for growth

Future Outlook

Acrotech's future looks promising, with plans to expand its portfolio through both internal R&D and strategic acquisitions. The company is also preparing to commercialize a biosimilar pipeline in the immuno-oncology space through its sister company CuraTeq[2].

As the pharmaceutical landscape continues to evolve, Acrotech's focused strategy and patient-centric approach position it well for continued growth and success.

Key Takeaways

  1. Acrotech Biopharma has quickly established itself as a significant player in oncology and hematology since its founding in 2018.
  2. The company's strategic acquisition of seven FDA-approved products from Spectrum Pharmaceuticals was a game-changer.
  3. Acrotech's focused strategy on niche areas within oncology allows it to compete effectively with larger pharmaceutical companies.
  4. The company's patient-centric approach, including programs like STAR, enhances its market position.
  5. Acrotech's global partnerships and plans for biosimilar development indicate potential for future growth.
  6. While facing challenges such as competition and regulatory hurdles, Acrotech's strategic positioning offers numerous opportunities for expansion and innovation.

FAQs

  1. Q: What is Acrotech Biopharma's primary focus? A: Acrotech Biopharma primarily focuses on developing and commercializing innovative medications in oncology and hematology, with a particular emphasis on rare and uncommon diseases.

  2. Q: How did Acrotech quickly establish its market presence? A: Acrotech rapidly established its market presence through the strategic acquisition of seven FDA-approved hematology/oncology products from Spectrum Pharmaceuticals in 2019.

  3. Q: What sets Acrotech apart from its competitors? A: Acrotech differentiates itself through its focused strategy on niche areas within oncology, its patient-centric approach, and its emphasis on "diamonds-in-the-rough" - drugs with improved efficacy or safety over current treatments.

  4. Q: How is Acrotech expanding globally? A: Acrotech is expanding globally through strategic partnerships covering major markets including the EU, Canada, Japan, China, and Latin America.

  5. Q: What are Acrotech's plans for future growth? A: Acrotech plans to expand its portfolio through internal R&D and strategic acquisitions, and is preparing to commercialize a biosimilar pipeline in the immuno-oncology space through its sister company CuraTeq.

Sources cited: [1] https://acrotechbiopharma.com [2] https://www.aurobindo.com/our-business/acrotech [3] https://acrotechbiopharma.com/acrotech-biopharma-to-buy-seven-drugs-from-spectrum-for-300m/ [4] https://canvasbusinessmodel.com/blogs/competitors/pfizer-competitive-landscape [5] https://rocketreach.co/acrotech-biopharma-inc-profile_b45313e0fc83bcd1 [6] https://acrotechbiopharma.com/acquisition-for-an-upfront-purchase-price-of-160-million-in-cash-plus-up-to-140-million-on-achieving-regulatory-and-sales-based-milestones/ [7] https://acrotechpatientaccess.com/patient-assistance-program/ [9] https://www.biospace.com/a-platform-for-hope-in-the-face-of-rare-and-uncommon-diseases

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.